San Diego, USA-based pioneer in non-invasive, AI-based arrhythmia analysis technology, Vektor Medical raised USD 16 million Series A investment. The round took place on February 5, 2024. Solas BioVentures and TVM Capital Life Science co-led the financing for the company.
Purpose of financing for the company
The latest funding supports the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool. The tool further transforms how EPs approach ablation procedures. To bolster this expansion, Vektor has plans to increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation, as well as continue efforts to secure reimbursement.
What the company’s official has to add
Rob Krummen, CEO of Vektor Medical, said, “The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency. vMap presents a solution to this challenge. Leading electrophysiologists (EPs) around the U.S. are utilizing vMap to streamline ablation procedures and improve patient outcomes. With the investment from Solas and TVM, we can expand access to this groundbreaking technology.”
What the investors have to comment
Dr. David Adair, Managing Director of Solas BioVentures, further said, “At Solas, we invest in game-changing healthcare innovation and strong leadership teams committed to creating meaningful patient impact. Vektor is addressing a massive problem in the cardiac arrhythmia space, giving millions of patients a chance to lead healthy lives free from this debilitating disease once again. We are thrilled to partner with the team and support Vektor’s unwavering commitment to challenging the status quo across the entire cardiac arrhythmia pathway, making it easier and faster for physicians and health systems to access this breakthrough technology.”
Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said, “Changing the standard of care demands a unique and transformative approach. vMap has been embraced by EPs focused on excellence. With increased resources, Vektor will scale adoption across the US and Europe. Patients and healthcare providers deserve better, and Vektor is ushering in that transition. We’re thrilled to invest and partner with Vektor to drive this important healthcare transformation.”
About the company
Mike Monko is the founder of the company. Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency.
To explore more such startups, visit Zefyron Startup Database
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
